Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Mirati Therapeutics joins Cancer Research UK’s lung cancer programme

National Lung Matrix Trial aims to assess a number of new drugs for the treatment of NSCLC. Credit: Cancer Research UK.



  • Mirati Therapeutics

Go Top